Analysis of Expansion Mesenchymal Stromal Cells in patients with low risk myelodysplastic syndrome

Authors

  • Fernando Barroso Duarte Department of Surgery, Federal University of Ceará - Brazil
  • Romélia Pinheiro Gonçalves Lemes Research Laboratory in Hemoglobinopathies and Genetics of Hematologic Diseases, Federal University of Ceará – Brazil
  • João Paulo Vasconcelos Department of Surgery, Federal University of Ceará - Brazil
  • Francisco Dário Rocha Department of Surgery, Federal University of Ceará - Brazil
  • Ilana Zalcberg Department of Surgery, Federal University of Ceará - Brazil
  • Diego Coutinho Department of Surgery, Federal University of Ceará - Brazil
  • Lúcia Silla Cellular Therapy Center of Hospital de Clinicas de Porto Alegre, Center for Experimental Research, Porto Alegre - Rio Grande do Sul – Brazil
  • Vanessa Valim Cellular Therapy Center of Hospital de Clinicas de Porto Alegre, Center for Experimental Research, Porto Alegre - Rio Grande do Sul – Brazil
  • Maritza Cavalcante Barbosa Research Laboratory in Hemoglobinopathies and Genetics of Hematologic Diseases, Federal University of Ceará – Brazil
  • Talyta Ellen de Jesus dos Santos Research Laboratory in Hemoglobinopathies and Genetics of Hematologic Diseases, Federal University of Ceará – Brazil
  • Luciana Barros Carlos Laboratorio de Criobiologia do Hemoce
  • Paulo Leitão de Vasconcelos Department of Surgery, Federal University of Ceará - Brazil

DOI:

https://doi.org/10.46765/2675-374X.2020v1n1p8-14

Keywords:

MDS, Hematopoietic cells, Mesenchymal cells, TP53 mutation

Abstract

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal hematopoiet­ic disorders characterized by ineffective hematopoiesis, cytopenias and dysplasia and one or more lineages. The stratification of MDS is made based on the percentage of bone marrow blasts, number of cytopenias and karyotype at diagnosis. Somatic mutations in the p53 tu­mor suppressor gene are found in approximately 50% of all human tumors, making it the most commonly mutated gene. The expression of p53 protein and the study of mutations is especially needed in the prognosis of MDS. In this context, the study aims to evaluate the expansion of mesenchymal stromal cells (MSCs) and the expression of p53 protein in pa­tients with SMD, low risk, according to the International Prognostic System (IPSS), in order to demonstrate the importance of these evaluations also diagnostics. This is a cross-sectional analytical study with review 3 adult patients of both sexes, the diagnosis of low-risk MDS receiving outpatient treatment at the University Hospital Walter Cantídio (HUWC). MSCs were characterized by immunophenotyping and screening of mutation of the p53 gene by Real Time PCR System (Applied Biosystems). For data analysis, the statistical software was used GraphPadPrism 5.0. Statistical differences between groups were checked by Student t or Mann-Whitney’s test significance level was p < 0.05 for all analyzes. The results showed a smaller expansion of MSCs in the bone marrow of patients with MDS compared with a control group. A survey of mutation of the p53 gene was negative in all patients. The results demonstrate an impairment in the growth of MSCs in patients with MDS, collaborating with the hypothesis that medullary microenvironment in MDS may be compromised contributing greater understanding of disease mechanisms. However studies with larger sample should be conducted in order to establish the best results.

Downloads

Published

07/06/2020

How to Cite

Duarte, F. B., Lemes, R. P. G., Vasconcelos, J. P., Rocha, F. D., Zalcberg, I., Coutinho, D., Silla, L., Valim, V., Barbosa, M. C., Santos, T. E. de J. dos, Carlos, L. B., & Vasconcelos, P. L. de. (2020). Analysis of Expansion Mesenchymal Stromal Cells in patients with low risk myelodysplastic syndrome. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 1(2), 8–14. https://doi.org/10.46765/2675-374X.2020v1n1p8-14

Most read articles by the same author(s)

1 2 > >>